info@mail.ucallm.com
1. Overview
The Cell-Free Protein Expression System is a technological platform that utilizes transcriptional and translational machineries derived from cell lysates or purified recombinant components to efficiently synthesize target proteins in vitro, without the involvement of intact living cells. By physically or chemically disrupting cells, the system contains essential biological components including ribosomes, tRNAs, aminoacyl-tRNA synthetases, translation factors, energy regeneration systems, and regulatory elements. These are supplemented with nucleotides, amino acids, energy substrates, and gene templates (DNA or mRNA) to directly initiate protein synthesis in test tubes or microplates.
Unlike traditional living cell expression systems, cell-free systems completely decouple protein synthesis from cell growth and metabolism. Without the need to maintain cell viability, they bypass constraints such as cell membrane barriers, metabolic regulation, and cytotoxicity, enabling rapid, efficient, and flexible protein synthesis in an open, controllable reaction environment. The technology originated from the pioneering work of Nirenberg and Matthaei in the 1960s, who used E. coli lysates to decipher the genetic code. Over decades of development, it has evolved from a basic research tool into an important technology platform in synthetic biology, biomanufacturing, and therapeutic protein development.
2. Core Advantages
(1) Extremely rapid expression: Cell-free expression eliminates time-consuming steps such as cloning, transformation, and cell culture. A typical CFPS reaction completes target protein synthesis within hours. Some optimized systems can generate detectable protein expression within several hours.
(2) Open and controllable reaction system: The reaction environment is completely open, allowing researchers to freely regulate pH, ionic strength, redox potential, cofactor concentrations, and other parameters without constraints from cell membrane barriers or in vivo regulatory networks.
(3) High throughput and parallelization: Without the need to culture multiple strains separately, different DNA templates can be used to simultaneously screen tens to hundreds of protein variants in 96- or 384-well plates, making it ideal for iterative screening in conjunction with AI-driven design.
(4) Bypassing cytotoxicity limitations: Since lysates have lost biological viability, toxic proteins cannot damage the "host," enabling safe expression of some toxic proteins and difficult-to-express proteins in traditional cell-based systems.
(5) Flexible template formats: In addition to plasmid DNA templates, PCR products or mRNA can be used directly as templates, eliminating tedious cloning steps.
(6) Efficient incorporation of non-natural amino acids: Without cell membrane barriers and avoiding cellular toxicity associated with non-natural amino acids, cell-free systems efficiently enable site-specific incorporation of non-natural amino acids into proteins.
(7) Portability and on-demand production: The system can be easily lyophilized for storage and transportation, and activated on-site when needed, enabling portable diagnostics and distributed biomanufacturing applications
(8) Compatibility with automation: Cell-free reactions can be seamlessly integrated with automated liquid handling platforms for fully automated workflows from DNA to purified protein.
3. System Limitations
(1) Limited post-translational modification capacity: Prokaryotic cell-free systems (e.g., E. coli lysate) lack eukaryotic PTM capabilities such as glycosylation; eukaryotic systems (e.g., wheat germ, rabbit reticulocyte) can perform some modifications but generally provide less extensive PTMs compared with mammalian cell expression systems
(2) Short reaction duration: Due to the absence of intracellular self-regeneration and homeostasis mechanisms, the reaction duration and cumulative yield are generally lower than living-cell systems
(3) Scalability challenges: Although liter-scale production has been demonstrated, while industrial-scale manufacturing remains under development compared to mature cell-based fermentation processes.
(4) Higher costs: Particularly for eukaryotic cell-free systems (e.g., rabbit reticulocyte, wheat germ), lysate preparation costs are relatively high.
(5) Protein stability issues: Without the protection of cell membranes, cell-free systems are more susceptible to external conditions (temperature, pH, ionic strength), potentially leading to protein instability, aggregation, and degradation.
(6) Endotoxin contamination risk: E. coli-based cell-free systems may have endotoxin residues.
4. Key Application Areas
(1) Antibody production: Rapid synthesis of full-length monoclonal antibodies and antibody fragments (VHH, scFv, Fab), overcoming challenges of low expression and activity in traditional cell-based systems. CFPS can enable rapid antibody fragment and protein expression within hours to days depending on the system and target., with activity comparable to mammalian cell-expressed antibodies. For example, anti-HER2 scFv antibody fragments for tumor targeting research.
(2) Membrane protein production: High-success-rate expression of full-length transmembrane proteins, addressing issues of aggregation and low activity in traditional systems. High soluble expression yields can be achieved by incorporating detergents, lipids, or Nanodiscs. Examples include CLDN 18.1 tight junction protein for antibody drug development and GPCRs for drug screening.
(3) Toxic protein expression: Bypassing cytotoxicity limitations, enabling stable synthesis of toxic molecules difficult to express in traditional systems. Examples include BamHI restriction endonuclease, antimicrobial peptides, and apoptosis-related proteins (e.g., Bax, Caspase-3).
(4) Vaccine development: Rapid response to pathogens via lyophilized lysate rehydration technology, rapid prototyping of vaccine antigens and bioconjugate vaccine candidates. Examples include Francisella tularensis vaccine antigens and Plasmodium surface proteins for malaria vaccine development.
(5) Non-natural amino acid incorporation: Site-specific introduction of fluorescent labels, isotope labels, or crosslinking groups for direct use in NMR or X-ray crystallography. Examples include incorporation of p-acetylphenylalanine for site-specific protein labeling and selenomethionine for structural determination.
(6) Enzyme engineering and directed evolution: High-throughput expression and screening of large enzyme mutant libraries, accelerating directed evolution workflows. Integration of machine learning with CFPS enables rapid construction of large-scale protein sequence-function datasets. Examples include directed evolution of glucose oxidase and cellulase.
(7) Drug target validation: Protein expression completed within hours, suitable for drug target validation and antibody engineering. Examples include EGFR ectodomain for antibody screening and KRAS mutants for targeted drug validation.
(8) Synthetic biology and metabolic engineering: Construction of multi-enzyme cascade reactions for synthesis of high-value bioproducts. Development of biosensors for real-time environmental pollutant detection. Examples include artemisinin precursor biosynthesis and heavy metal ion biosensors.
5. Design Elements of Cell-Free Expression Templates
Vector design for cell-free expression systems differs from traditional cell-based expression vectors, with key features including:
l Promoter: T7 promoter is widely used in bacterial lysate-based CFPS systems requiring T7 RNA polymerase. Some vectors also support SP6 or T3 promoters.
l Ribosome Binding Site/Translation Initiation Sequence: Prokaryotic systems require an effective RBS sequence (Shine-Dalgarno sequence) to initiate translation, while eukaryotic systems require a Kozak consensus sequence for efficient ribosomal scanning and translation initiation.
l Fusion Tags: His tags are commonly used for purification, and Xpress tags for detection. Some vectors offer screening of multiple fusion tags.
l Transcription Termination Signal: Ensures accurate transcription termination.
5.1 By promoter/system type
Type | Promoter/System | Features | Suitable System |
T7 promoter vectors | T7 | Highest transcription efficiency | E. coli lysate system |
SP6 promoter vectors | SP6 | Suitable for SP6 RNA polymerase systems | E. coli, wheat germ systems |
T3 promoter vectors | T3 | Suitable for T3 RNA polymerase systems | E. coli lysate system |
Wheat germ optimized vectors | Specialized regulatory elements | Optimized for wheat germ system | Wheat germ system |
Rabbit reticulocyte vectors | Specialized regulatory elements | Optimized for rabbit reticulocyte system | Rabbit reticulocyte system
|
5.2 By expression product format
Type | Features | Representative Vectors |
Non-fusion Protein Vectors | No fusion tags; yields native protein | pIVEX2.1 Native, pET with modified cloning sites |
Fusion Protein Vectors | N- or C-terminal affinity tags for purification and detection | pEXP1-DEST, pIVEX series |
Self-cleavage Vectors | Contains intein self-cleavage elements for tag removal | pTXB1 (intein system) |
6. Common Lysate Sources and System
System Type | Source | Yield | PTMs | Cost | Application |
E. coli Lysate | E. coli | Very High | None | Low | High-throughput screening, high-yield production, prokaryotic proteins |
Wheat Germ | Wheat germ | High | Limited | Medium | Eukaryotic proteins, membrane proteins, plant proteins |
Rabbit Reticulocyte | Rabbit reticulocyte | Low | Partial | High | Mammalian proteins, Limited eukaryotic processing |
Insect Cell Lysate | Sf9/Sf21 cells | Medium | Partial | Medium | Eukaryotic proteins, complex proteins |
Mammalian Cell Lysate | CHO/HEK293/HeLa | Medium-High | More extensive mammalian-like processing capability | High | Proteins requiring native PTMs |
PURE | Purified recombinant components | Medium | None | High | Experiments requiring no background proteins, synthetic biology |
7. Selection Guide
Requirement | Recommended System/Vector | Reason |
High-throughput protein screening | E. coli lysate system + linear PCR templates | Low cost, high yield, suitable for microplate operation |
High-yield protein production | E. coli lysate system + pET/pIVEX series | High yield among CFPS platforms |
Membrane protein expression | Wheat germ system / E. coli system + detergent/Nanodisc | Eukaryotic folding environment or lipid-supplemented environment |
Toxic protein expression | Any cell-free system + E. coli lysate (most common) | No cytotoxicity limitations |
Proteins requiring PTMs | Rabbit reticulocyte / mammalian cell lysate | Provides eukaryotic PTM capabilities |
Non-natural amino acid incorporation | E. coli lysate system / PURE system | No cell membrane barrier, high incorporation efficiency |
No background protein interference | PURE system | Defined composition, no endogenous nucleases or proteases |
Plant protein expression | Wheat germ system | Expression environment close to native |
Isotope-labeled proteins (NMR/crystallography) | E. coli lysate system | Low cost, high labeling efficiency |
8.Service Highlights
l Rapid Delivery: From DNA template to purified protein within several days depending on target complexity
l High-Throughput Screening: Supports 96/384-well plate parallel expression; a single project can support large-scale parallel screening workflows.
l Expertise in Challenging Targets: Proprietary solutions for membrane proteins, toxic proteins, proteins requiring disulfide bonds, and other difficult targets.
l Multiple System Options: E. coli, wheat germ, rabbit reticulocyte, and other cell-free systems to meet diverse expression needs.
l Flexible Template Formats: Supports plasmid DNA, PCR products, and mRNA templates.
l Non-natural Amino Acid Incorporation: Supports isotope labeling, selenoamino acid labeling, and site-specific non-natural amino acid incorporation.
l Automation-Compatible: Seamless integration with automated liquid handling platforms for high-throughput automated protein expression and screening.
9.Service Procedure
Service Step | Gene synthesis and vector construction (Optional) | Cell-free expression and purification | Scale-Up Expression and Purification |
Description | l Provide sequence l Codon optimization l Cloning into expression vectors l Plasmid validation & preparation | l Selection of appropriate cell-free system l Expression & purification trial l Protein expression evaluation (SDS-PAGE, UV, etc) | l Large-scale expression & purification l QC analysis
|
Deliverables | l Plasmid sequence l COA report | l Expression evaluation result | l Purified proteins l COA report |
Turnaround Times | 2-6 days | 1-2 days | 1-2 weeks |
10. Case Studies
11.Frequently Asked Questions (FAQs)
l Q1: What are the advantages of cell-free protein expression over traditional cell-based expression?
A: First, short reaction cycles—protein expression is completed in hours to one day. Second, high throughput—parallel expression in microplates with automation. Third, broad protein applicability—can express membrane proteins, toxic proteins, and other proteins difficult to express in traditional systems. Fourth, high flexibility and controllability—enables incorporation of non-natural amino acids, etc.
l Q2: Can cell-free systems express membrane proteins?
A: Yes. By adding appropriate detergents or Nanodiscs to the reaction system to provide a membrane-like environment, cell-free systems can efficiently express full-length transmembrane proteins. Successful expression of single-pass, four-pass, and seven-pass transmembrane proteins has been reported, with expression success rates approaching 100%.
l Q3: Are proteins expressed in cell-free systems active?
A: Yes. By controlling reaction temperature, adding chaperones and auxiliary factors, proper protein folding can be achieved. Synthesized proteins exhibit activity comparable to proteins produced by conventional expression systems for selected targets
l Q4: What yields can cell-free systems achieve?
A: Yields generally depend on the target protein, ranging from μg/mL to hundreds of μg/mL, with some specialized optimized systems have reported mg/mL-level yields.